Overview

SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Status:
Completed

Trial end date:
2008-04-01

Target enrollment:

Participant gender:

Summary

Ranibizumab is a humanised recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A. This study will assess the safety and efficacy of ranibizumab administered on an as-needed dosing regimen in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Ranibizumab